cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Amphastar Pharmaceuticals Inc
7 own
24 watching
Current Price
$30.26
$-0.03
(-0.1%)
logo-amph
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,471.02M
52-Week High
52-Week High
44.46
52-Week Low
52-Week Low
22.97
Average Volume
Average Volume
0.27M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
95.1793
iconMarket Capitalization1,471.02M
icon52-Week High44.46
icon52-Week Low22.97
iconAverage Volume0.27M
iconDividend Yield--
iconP/E Ratio95.1793
What does the Amphastar Pharmaceuticals Inc do?
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, which include critical care drugs, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; and procainamide for documented ventricular arrhythmias. In addition, the company manufactures and distributes recombinant human insulin and porcine insulin. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate that is intended to be used for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. The company was established in 1996 and is headquartered in Rancho Cucamonga, California.
Read More
How much money does Amphastar Pharmaceuticals Inc make?
News & Events about Amphastar Pharmaceuticals Inc.
Accesswire
3 months ago
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30, 2022, after the market closes on Monday, November 7, 2022, and will hold a conference call to...
Accesswire
5 months ago
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sales and Marketing and Tony Marrs Sr. Vice President of Regulatory Affairs and Clinical Operations...
Zolmax
5 months ago
Principal Financial Group Inc. reduced its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH Get Rating) by 5.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 266,904 shares of the companys stock after ...
Zolmax
5 months ago
Los Angeles Capital Management LLC acquired a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH Get Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 5,635 shares of the companys ...
Ticker Report
7 months ago
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH Get Rating) Director Howard Lee sold 10,291 shares of the firms stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $37.79, for a total transaction of $388,896.89. Following the sale, the ...
Frequently Asked Questions
Frequently Asked Questions
What is Amphastar Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Amphastar Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Amphastar Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Amphastar Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Amphastar Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Amphastar Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Amphastar Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Amphastar Pharmaceuticals Inc?
plus_minus_icon
What percentage is Amphastar Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Amphastar Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$30.26
$-0.03
(-0.1%)
logo-amph
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00